The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press2710.17650/1818-8338-2013-7-2-180-197ORIGINAL INVESTIGATIONSОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕQUALITY OF LIFE IN PATIENTS WITH HYPERTENSION, CORONARY HEART DISEASE, AND ATHEROSCLEROTIC LESION OF LOWER EXTREMITY ARTERIES IN THE SECONDARY PREVENTION OF COMPLICATIONSКачество жизни пациентов с артериальной гипертензией, ишемической болезнью сердца и атеросклеротическим поражением артерий нижних конечностей при проведении вторичной профилактики осложненийKarlovA. A.КарловА. А.
Russian Federation

Department of Cardiology

Кафедра кардиологии

dr_owl@land.ruKarlovaN. A.КарловаН. А.
Russian Federation

Department of Cardiology

Кафедра кардиологии

ZolozovaE. A.ЗолозоваЕ. А.
Russian Federation

Department of Cardiology

Кафедра кардиологии

SayutinaE. V.СаютинаЕ. В.
Russian Federation

Department of Cardiology

Кафедра кардиологии

ChiginevaV. V.ЧигиневаВ. В.
Russian Federation

Department of Cardiology

Кафедра кардиологии

Russian Medical Academy of Postgraduate Education, Ministry of Health of RussiaГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России150420137234391407201414072014Copyright ©; 2013, Karlov A.A., Karlova N.A., Zolozova E.A., Sayutina E.V., Chigineva V.V.Copyright ©; 2013, Карлов А.А., Карлова Н.А., Золозова Е.А., Саютина Е.В., Чигинева В.В.2013Karlov A.A., Karlova N.A., Zolozova E.A., Sayutina E.V., Chigineva V.V.Карлов А.А., Карлова Н.А., Золозова Е.А., Саютина Е.В., Чигинева В.В.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/27

Atherosclerotic lesion of lower extremity arteries frequently complicates the long-term course of hypertension and it is generally associated with coronary heart disease. Our study has attempted to evaluate the impact of combination antihypertensive therapy involving amlodipine, bisoprolol, and lisinopril on quality of life in this category of patients.

Атеросклеротическое поражение артерий нижних конечностей часто осложняет длительное течение артериальной гипертензии и, как правило, сочетается с ишемической болезнью сердца. В нашем исследовании предпринята попытка оценить влияние комплексной гипотензивной терапии, включающей амлодипин, бисопролол и лизиноприл, на качество жизни этой категории пациентов.

hypertensioncoronary heart diseaseatherosclerotic lesion of lower extremity arteriesquality of lifeamlodipinebisoprolollisinoprilартериальная гипертензияишемическая болезнь сердцаатеросклеротическое поражение артерий нижних конечностейкачество жизниамлодипинбисопрололлизиноприл1. Бузиашвили Ю.И. Диагностика и лечение мультифокального атеросклероза. В кн.: Лекции по кардиологии. Под ред. Л.А. Бокерия, Е.З. Голуховой. М.: Изд-во НЦССХ им. А.Н. Бакулева РАМН, 2001. T. 2. С. 142–61.Бузиашвили Ю.И. Диагностика и лечение мультифокального атеросклероза. В кн.: Лекции по кардиологии. Под ред. Л.А. Бокерия, Е.З. Голуховой. М.: Изд-во НЦССХ им. А.Н. Бакулева РАМН, 2001. T. 2. С. 142–61.2. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases ofESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases ofthe European Society of Cardiology (ESC). Eur Heart J 2011;32(22):2851–906.3. Nehler M.R., McDermott M.M., Treat-Jacobson D. et al. Functional outcomes and quality of Life in peripheral arterial disease: current status. Vasc Med 2003;8(2):115–26.Nehler M.R., McDermott M.M., Treat-Jacobson D. et al. Functional outcomes and quality of Life in peripheral arterial disease: current status. Vasc Med 2003;8(2):115–26.4. Hiatt W.R., Nawaz D., Regensteiner J.G., Hossack K.F. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulmonary Rehabil 1988;12:525–32.Hiatt W.R., Nawaz D., Regensteiner J.G., Hossack K.F. The evaluation of exercise performance in patients with peripheral vascular disease. J Cardiopulmonary Rehabil 1988;12:525–32.5. Nicolaï S.P., Kruidenier L.M., Rouwet E.V. et al. The walking impairment questionnaire: An effective tool to assess the effect of treatment in patients with intermittent claudication. J Vasc SurgNicolaï S.P., Kruidenier L.M., Rouwet E.V. et al. The walking impairment questionnaire: An effective tool to assess the effect of treatment in patients with intermittent claudication. J Vasc Surg2009;50(1):89–94.;50(1):89–94.6. Ikeda S., Kobayashi M., Shigematsu H. et al. Development of the Japanese Version of Walking Impairment Questionnaire (WIQ). J Jpn Coll Angiol 2005;45(4):233–40.Ikeda S., Kobayashi M., Shigematsu H. et al. Development of the Japanese Version of Walking Impairment Questionnaire (WIQ). J Jpn Coll Angiol 2005;45(4):233–40.7. Collins T.C., Suarez-Almazor M., Petersen N.J., O'Malley K.J. A Spanish translation of the Walking Impairment Questionnaire was validated for patients with peripheral arterial disease. J Clin EpidemiolCollins T.C., Suarez-Almazor M., Petersen N.J., O'Malley K.J. A Spanish translation of the Walking Impairment Questionnaire was validated for patients with peripheral arterial disease. J Clin Epidemiol2004;57(12):1305–15.;57(12):1305–15.8. Jie Wang, Yan Cui, Bian R.W. et al. Validation of the Chinese version of the Walking ImpairmentJie Wang, Yan Cui, Bian R.W. et al. Validation of the Chinese version of the Walking ImpairmentQuestionnaire in patients with both peripheral arterial disease and type 2 diabetes mellitus. Diab Vasc Dis Res 2011;8(1):29–34.9. Hiatt W.R., Regensteiner J.G., Creager M.A. et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110(8):616–22.Hiatt W.R., Regensteiner J.G., Creager M.A. et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110(8):616–22.10. Рогоза А.Н., Балахонова Т.В., Чихладзе Н.М. Методы определения лодыжечно-плечевого индекса систолического давления при массовых обследованиях. Consilium Medicum 2009;11(10):66–71.Рогоза А.Н., Балахонова Т.В., Чихладзе Н.М. Методы определения лодыжечно-плечевого индекса систолического давления при массовых обследованиях. Consilium Medicum 2009;11(10):66–71.11. Regensteiner J.G., Steiner J.F., Hiatt W.R. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23(1):104–15.Regensteiner J.G., Steiner J.F., Hiatt W.R. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23(1):104–15.12. Dilie M., Mlaco A., Helji- B. et al. Arterial hypertension as a risk factor multifocal atherosclerosis. Med Arh 2002;56(2):93–6.Dilie M., Mlaco A., Helji- B. et al. Arterial hypertension as a risk factor multifocal atherosclerosis. Med Arh 2002;56(2):93–6.13. Pitt B., Byngton R.P., Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102(3):1503–10.Pitt B., Byngton R.P., Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102(3):1503–10.14. Rana R., Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. The Indian Practitioner 2008; 61(4):225–34.Rana R., Patil A. Efficacy and safety of bisoprolol plus amlodipine fixed dose combination in essential hypertension. The Indian Practitioner 2008; 61(4):225–34.15. Black H.R., Davis B., Barzilay J. et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment forBlack H.R., Davis B., Barzilay J. et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment forhypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008;31(2):353–60.16. Brilla C.G., Funck R.C., Rupp H. Lisinoprilmediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102(12):1388–93.Brilla C.G., Funck R.C., Rupp H. Lisinoprilmediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102(12):1388–93.17. Агеев Ф.Т., Смирнова М.Д., Фофанова Т.В. Повышение приверженности к терапии: «дело техники»? Сердечн недостат 2011;12(4):238–43.Агеев Ф.Т., Смирнова М.Д., Фофанова Т.В. Повышение приверженности к терапии: «дело техники»? Сердечн недостат 2011;12(4):238–43.18. Benson J., Britten N. Patients' views about taking antihypertensive drugs: questionnaire study. BMJ 2003;326:1314–5.Benson J., Britten N. Patients' views about taking antihypertensive drugs: questionnaire study. BMJ 2003;326:1314–5.